THP-1 macrophages were treated with (A) nicotinamide (5 mM) or cyclosporin A (CsA, 5 μM) and (C) the RIPK3 inhibitor GSK´872 (10 μM) or the MLKL inhibitor necrosulfonamide (NSA, 10 μM), and infected with Mtb strains at an MOI of 10:1 for 48 h. ROS levels (measured with the fluorescent probe H2DCFDA) were analyzed. (B) THP-1 macrophages were treated with necrostatin-1s (Nec-1s, 10 μM), GSK’872 (10 μM), necrosulfonamide (NSA, 10 μM) and/or TNF-a, cycloheximide, and zVAD-fmk (T/C/Z) (Cho et al., 2009), and cell viability was measured by trypan blue. Asterisks indicate significant differences (p-value<0.01, calculated using the One-way [B] or Two-way [A, C] ANOVA with Bonferroni’s correction) compared with the indicated conditions. Data are represented as mean ± SEM.